Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Long-Term Debt Repayments (2022 - 2025)

Pulmonx (LUNG) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $1000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $97000.0, a 7.78% increase, with the full-year FY2024 number at $95000.0, up 1.06% from a year prior.
  • Long-Term Debt Repayments was $1000.0 for Q3 2025 at Pulmonx, down from $49000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $49000.0 in Q4 2024 to a low of $1000.0 in Q3 2025.
  • A 4-year average of $35000.0 and a median of $45000.0 in 2022 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: increased 9.3% in 2023, then grew 4.26% in 2024.
  • Pulmonx's Long-Term Debt Repayments stood at $43000.0 in 2022, then grew by 9.3% to $47000.0 in 2023, then rose by 4.26% to $49000.0 in 2024, then crashed by 97.96% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Long-Term Debt Repayments are $1000.0 (Q3 2025), $49000.0 (Q4 2024), and $47000.0 (Q4 2023).